Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
1.1700 x 6 1.1900 x 347
Post-market by (Cboe BZX)
1.1600 +0.1000 (+9.43%) 04/23/25 [NASDAQ]
1.1700 x 6 1.1900 x 347
Post-market 1.1900 +0.0300 (+2.59%) 19:52 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.1100
Day High
1.2000
Open 1.1200
Previous Close 1.0600 1.0600
Volume 3,059,800 3,059,800
Avg Vol 4,313,955 4,313,955
Stochastic %K 93.82% 93.82%
Weighted Alpha +1.74 +1.74
5-Day Change +0.3256 (+39.02%) +0.3256 (+39.02%)
52-Week Range 0.6300 - 2.7500 0.6300 - 2.7500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,555
  • Shares Outstanding, K 53,354
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,520 K
  • EBIT $ -42 M
  • EBITDA $ -42 M
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.10

Options Overview Details

View History
  • Implied Volatility 260.38% ( -77.69%)
  • Historical Volatility 295.34%
  • IV Percentile 76%
  • IV Rank 29.74%
  • IV High 645.74% on 04/03/25
  • IV Low 97.25% on 12/31/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 281
  • Volume Avg (30-Day) 1,172
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 15,578
  • Open Int (30-Day) 20,450

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 4
  • High Estimate -0.11
  • Low Estimate -0.24
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +9.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6300 +84.13%
on 04/09/25
Period Open: 1.9000
2.3600 -50.85%
on 03/27/25
-0.7400 (-38.95%)
since 03/21/25
3-Month
0.6300 +84.13%
on 04/09/25
Period Open: 2.0500
2.4991 -53.58%
on 03/17/25
-0.8900 (-43.41%)
since 01/23/25
52-Week
0.6300 +84.13%
on 04/09/25
Period Open: 1.7000
2.7500 -57.82%
on 12/31/24
-0.5400 (-31.76%)
since 04/23/24

Most Recent Stories

More News
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive

The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.

MIST : 1.1600 (+9.43%)
GWX : 33.08 (-0.03%)
FDA Issues Complete Response Letter for Etripamil for PSVT

MIST : 1.1600 (+9.43%)
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

MIST : 1.1600 (+9.43%)
Milestone Pharmaceuticals: Q4 Earnings Snapshot

Milestone Pharmaceuticals: Q4 Earnings Snapshot

MIST : 1.1600 (+9.43%)
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

MIST : 1.1600 (+9.43%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIST : 1.1600 (+9.43%)
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

MIST : 1.1600 (+9.43%)
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

MIST : 1.1600 (+9.43%)
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

MIST : 1.1600 (+9.43%)
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

MIST : 1.1600 (+9.43%)

Business Summary

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.2933
2nd Resistance Point 1.2467
1st Resistance Point 1.2033
Last Price 1.1600
1st Support Level 1.1133
2nd Support Level 1.0667
3rd Support Level 1.0233

See More

52-Week High 2.7500
Fibonacci 61.8% 1.9402
Fibonacci 50% 1.6900
Fibonacci 38.2% 1.4398
Last Price 1.1600
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective